Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005 Jan 01; 105(1):49-53.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Disease Progression
Humans
Immunotherapy
Leukemia, Lymphocytic, Chronic, B-Cell
Middle Aged
Retrospective Studies
Rituximab
Survival Rate
Time Factors
Treatment Outcome
Vidarabine

authors with profiles

Richard A. Larson